Phosphodiesterase inhibition as a therapeutic target for brain ischemia.

Another interesting piece of research needing followup. But that won't occur until we destroy the existing failures of stroke associations. What a great stroke association would look like.
 httpha://europepmc.org/abstract/med/26350339

(PMID:26350339)

• Abstract
• Citations
• BioEntities
• Related Articles
• External Links

Soares LM, Prickaerts J, Milani H, Del Bel E, Steinbusch HW, de Oliveira RM

CNS & Neurological Disorders Drug Targets [2015]

Type: Journal Article

Abstract

Highlight Terms Diseases(2)

Preclinical studies have shown that phosphodiesterase inhibitors (PDE-Is) represent a potential pharmacological strategy for the treatment of brain ischemia sequelea. PDE-Is 3, 4 and 5 have been tested in several brain ischemia models. All the three PDE-Is after acute or chronic treatment decreased the degree of neurodegeneration and most of them improved functional recovery after brain injury by specific cellular and molecular mechanisms mainly involving an anti-inflammatory and/or neuroprotection action. In contrast to the large number of investigations using PDE-Is in experimental brain ischemia research, the number of clinical studies is still limited. The purpose of this review is to summarize the data currently available on the effects of PDE-Is in experimental models of cerebral ischemia.